Group 1 - The core point of the article highlights the trading activity of Kanghua Biological, which saw a slight increase in stock price by 0.21% to close at 75.66 yuan, with a significant block trade occurring [1] - The block trade involved a total volume of 56,800 shares and a transaction amount of 4.2975 million yuan, with a premium rate of 0.00% [1] - Over the past three months, Kanghua Biological has recorded two block trades with a cumulative transaction amount of 8.2009 million yuan [1] Group 2 - In the last five trading days, the stock has experienced a cumulative decline of 0.47%, with a net outflow of main funds totaling 5.6844 million yuan [1]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交星 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2026-01-16 | 300841 | 康华生物 | 75.66 | 5.68 | 429.75 | 中国中金财富证券 | 联储证券股份有限 | | | | | | | | 有限公司上海黄浦 | 公司陕西分公司 | | | | | | | | 区中山东二路证券 | | | | | | | | | 章业部 | | 1月16日，康华生物大宗交易成交5.68万股，成交额429.75万元，占当日总成交额的3.3%，成交价75.66元，较市场收盘价 75.66元持平。 ...

Group 1 - The core transaction of Kanghua Biological occurred on January 15, with a volume of 51,700 shares and a transaction amount of 3.9034 million yuan, at a price of 75.50 yuan per share [2][3] - The closing price of Kanghua Biological on the same day was 75.50 yuan, reflecting a decrease of 0.40%, with a turnover rate of 1.52% and a total transaction amount of 136 million yuan, indicating a net outflow of 4.3715 million yuan in main funds [2] - Over the past five days, the stock has increased by 2.03%, with a total net inflow of 576,400 yuan [2] Group 2 - The latest margin financing balance for Kanghua Biological is 1.035 billion yuan, which has increased by 16.5653 million yuan over the past five days, representing a growth rate of 1.63% [3] - Kanghua Biological was established on April 2, 2004, with a registered capital of 1.29946899 billion yuan [3]

Group 1 - The animal vaccine sector experienced a decline of 0.04%, ranking among the top losers in the concept sector, with notable declines from companies such as Hengtong Co., BioShares, and Kanghua Bio [1] - Among the animal vaccine stocks, 9 companies saw price increases, with Dongfang Bio, KQ Bio, and Haili Bio leading the gains at 2.23%, 0.87%, and 0.77% respectively [1] - The sector faced a net outflow of 212 million yuan from main funds, with 14 stocks experiencing outflows, and 7 stocks seeing outflows exceeding 10 million yuan, led by Roniu Mountain with a net outflow of 82.38 million yuan [2] Group 2 - The top stocks with net outflows included BioShares, Hengtong Co., and Kanghua Bio, with net outflows of 41.91 million yuan, 41.77 million yuan, and 24.74 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Dabeinong, Haili Bio, and Guoyao Modern, with net inflows of 32.76 million yuan, 6.20 million yuan, and 3.24 million yuan respectively [2] - The trading data indicated that Roniu Mountain had a trading rate of 8.05% and a price drop of 1.05%, while Dongfang Bio had a trading rate of 1.46% and a price increase of 2.23% [3]

Group 1 - The core viewpoint of the news is that Kanghua Biological has experienced fluctuations in stock price and financial performance, with a notable decrease in revenue and net profit year-on-year [1][2][3] Group 2 - As of January 9, Kanghua Biological's stock price increased by 2.03% to 75.50 CNY per share, with a total market capitalization of 9.811 billion CNY [1] - The company has seen a year-to-date stock price increase of 4.48%, but a decline of 4.50% over the past 20 days and 2.84% over the past 60 days [1] - Kanghua Biological's main business involves comprehensive research, development, and operation of vaccines, with 99.99% of its revenue coming from non-immunization planning vaccines [1] Group 3 - As of September 30, the number of shareholders for Kanghua Biological increased by 6.13% to 18,300, while the average number of circulating shares per person decreased by 8.10% to 6,502 shares [2] - For the period from January to September 2025, Kanghua Biological reported a revenue of 840 million CNY, a year-on-year decrease of 20.78%, and a net profit attributable to shareholders of 189 million CNY, down 53.41% year-on-year [2] Group 4 - Since its A-share listing, Kanghua Biological has distributed a total of 686 million CNY in dividends, with 462 million CNY distributed over the past three years [3] - As of September 30, 2025, the fifth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 1.1826 million shares as a new shareholder [3] - The seventh largest circulating shareholder is Southern CSI 1000 ETF, holding 850,600 shares, which is a decrease of 11,100 shares compared to the previous period [3]

Market Performance - The biopharmaceutical sector increased by 0.55% on January 6, with Liaoning Chengda leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Liaoning Chengda (600739) closed at 12.27, with a rise of 7.16% and a trading volume of 530,500 shares, amounting to a transaction value of 633 million yuan [1] - Dongbao Biological (300239) closed at 6.18, up by 5.64%, with a trading volume of 454,500 shares and a transaction value of 278 million yuan [1] - Olin Biological (616889) closed at 27.66, increasing by 3.83%, with a trading volume of 74,400 shares and a transaction value of 204 million yuan [1] - Kanghong Pharmaceutical (002773) closed at 33.75, up by 2.37%, with a trading volume of 249,700 shares and a transaction value of 838 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 323 million yuan [2] - The net inflow from speculative funds was 104 million yuan [2] Detailed Capital Flow for Selected Stocks - Liaoning Chengda had a net inflow of 34.37 million yuan from institutional investors, while it faced a net outflow of 18.32 million yuan from retail investors [3] - Dongbao Biological saw a net inflow of 21.29 million yuan from institutional investors, with a net outflow of 13.16 million yuan from retail investors [3] - Tian Tan Biological (600161) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow of 10.02 million yuan from retail investors [3]

Core Viewpoint - Chengdu Kanghua Biological Products Co., Ltd. has announced a prudent adjustment to the implementation schedule of its fundraising project "Vaccine Production Expansion Project," moving the expected completion date from December 31, 2025, to June 30, 2026 [1][2] Group 1: Project Adjustment Details - The adjustment only involves the project timeline and does not change the implementation entity, location, or the use of raised funds [1] - The project has completed workshop construction, equipment debugging, trial production, drug registration site inspection, GMP compliance checks, and is currently in the supplementary application review stage [1] Group 2: Regulatory and Management Insights - The adjustment is not due to project obstacles but is a necessary coordination with regulatory processes [2] - The company aims to ensure that the project operates in a fully compliant and stable manner by dynamically optimizing expectations based on actual approval rhythms [2] Group 3: Strategic Importance - The expansion project is a strategic move for Kanghua Biological to solidify core production capacity and align with future market demands [2] - Despite the short-term schedule adjustment, the completion of the main engineering and the most challenging review stages has not affected the long-term strategic value and potential contribution to performance [2]

Group 1 - The company, Kanghua Biological, announced that its third board meeting was held on December 29, 2025, via telecommunication voting [1] - The meeting reviewed the proposal regarding the adjustment of the implementation progress of certain fundraising investment projects [1]

Group 1 - Kanghua Biological announced that as of the date of the announcement, Wanke Xin has pledged a total of approximately 20.67 million shares, accounting for 72.63% of his holdings [1] - Wang Zhentao has pledged a total of approximately 10.46 million shares, which represents 99.61% of his holdings [1]

本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 成都康华生物制品股份有限公司（以下简称"公司"、"康华生物"）于 2025 年 12 月 29 日召开第三届董事会第十二次会议，审议通过了《关于调整部 分募集资金投资项目实施进度的议案》，同意公司对部分募集资金投资项目的实 施进度进行调整。上述事项在董事会的审议权限范围内，无需提交股东会审议。 现将有关事项公告如下： 一、募集资金基本情况 证券代码：300841 证券简称：康华生物 公告编号：2025-073 成都康华生物制品股份有限公司 关于调整部分募集资金投资项目实施进度的公告 经中国证券监督管理委员会《关于核准成都康华生物制品股份有限公司首次 公开发行股票的批复》（证监许可[2020]521 号）核准，公司首次公开发行人民 币普通股（A 股）1,500.00 万股，每股发行价为人民币 70.37 元，募集资金总额 为人民币 105,555.00 万元，扣除各项发行费用人民币 7,457.70 万元后，募集资金 净额为人民币 98,097.30 万元。募集资金到位情况业经立信会计师事务所（特殊 普通合伙）审验 ...